Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other financing activities (2020 - 2023)

Xeris Biopharma Holdings (XERS) has disclosed Other financing activities for 4 consecutive years, with $1.2 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Other financing activities rose 1875.0% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Dec 2023, down 75.7%, and an annual FY2023 reading of $1.2 million, down 75.7% over the prior year.
  • Other financing activities was $1.2 million for Q4 2023 at Xeris Biopharma Holdings, up from $60000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $3.6 million in Q1 2022 and bottomed at -$1.2 million in Q4 2020.
  • Average Other financing activities over 4 years is $697714.3, with a median of $159000.0 recorded in 2022.
  • The sharpest move saw Other financing activities surged 194.44% in 2022, then soared 1875.0% in 2023.
  • Year by year, Other financing activities stood at -$1.2 million in 2020, then surged by 104.39% to $54000.0 in 2021, then increased by 11.11% to $60000.0 in 2022, then skyrocketed by 1875.0% to $1.2 million in 2023.
  • Business Quant data shows Other financing activities for XERS at $1.2 million in Q4 2023, $60000.0 in Q4 2022, and $159000.0 in Q3 2022.